CMDh question to Safety Working Party (SWP) to determine the acceptable intake for nitrosamine N-nitroso-Mefanamic Acid based on lifetime daily exposure including information on the points of departure and methodology used.
Update on Q&A for marketing authorization holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products (EMA/409815/2020 Rev.6).
CMDh question to SWP to determine the acceptable intake for N-Nitroso-folic acid based on
lifetime daily exposure including information on the points of departure and methodology
used.
Action: For adoption
The CHMP adopted the updated Q&A on nitrosamines.
Thanks Andrew, I should had put my question as “nitroso compound”. My doubt was also related that when information is looked for this compounds the only difference in the naming is that the 2nd one is indicated as N10-nitroso folic acid because of the numbering, and the IARC indicate as “N-nitroso folic acid” to be the nitrosoamide. Thus better to be sure.